{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:12:31Z","timestamp":1789737151727,"version":"4.0.1"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Outcome of Multiple Myeloma (MM) patients has improved as the result of the introduction of novel medications and use of autologous hematopoietic cell transplantation. However, this improvement comes at the expense of increased financial burden. It is largely unknown if socioeconomic factors influence MM survival. Methods: We used the National Cancer Database, a database that houses data on 70% of cancer patients in the US, to evaluate the effect of socioeconomic factors on the survival of 117,926 MM patients diagnosed between 2005 and 2014. Results: Patients aged \u226565 years who were privately insured lived longer than patients with Medicare (42 months vs. 31 months, respectively, p &lt; 0.0001). Treatment in academic institutions led to better survival (HR: 1.49, 95% CI: 1.39, 1.59). Younger age, fewer comorbidities, treatment in academic centers, and living in a higher median income area were significantly associated with improved survival. After adjusting for confounders, survival of Medicare patients was similar to those with private insurance. However, the hazard of death remained higher for patients with Medicaid (HR: 1.59, 95% CI: 1.36, 1.87) or without insurance (HR: 1.62, 95% CI: 1.32, 1.99), compared to privately insured patients. Conclusion: Economic factors and treatment facility type play an important role in the survival of MM patients.<\/jats:p>","DOI":"10.3390\/cancers13040590","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T11:54:31Z","timestamp":1612353271000},"page":"590","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Socioeconomic Factors and Survival of Multiple Myeloma Patients"],"prefix":"10.3390","volume":"13","author":[{"given":"Kamal","family":"Chamoun","sequence":"first","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Firoozmand","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caimi","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-5218","authenticated-orcid":false,"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufen","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folashade","family":"Otegbeye","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland","family":"Metheny","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Patel","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-2549","authenticated-orcid":false,"given":"Stanton L.","family":"Gerson","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Boughan","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"De Lima","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Malek","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"655","article-title":"SEER Cancer Statistics Review 1975\u20132015","volume":"2015","author":"Noone","year":"2015","journal-title":"Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor Activity of Thalidomide in Refractory Multiple Myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma","volume":"19","author":"Costa","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/10428194.2017.1408086","article-title":"Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma","volume":"59","author":"Malek","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/cncr.29187","article-title":"Insurance status and risk of cancer mortality among adolescents and young adults","volume":"121","author":"Rosenberg","year":"2014","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2008.20.8025","article-title":"Insurance Status, Comorbidity Level, and Survival Among Colorectal Cancer Patients Age 18 to 64 Years in the National Cancer Data Base From 2003 to 2005","volume":"27","author":"Robbins","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1002\/cncr.29518","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.24774","article-title":"The impact of health insurance status on the survival of patients with head and neck cancer","volume":"116","author":"Kwok","year":"2009","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/cncr.28549","article-title":"Insurance status is related to diffuse large B-cell lymphoma survival","volume":"120","author":"Han","year":"2014","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/cncr.30183","article-title":"Impact of marital status, insurance status, income, and race\/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States","volume":"122","author":"Costa","year":"2016","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cncr.22788","article-title":"The impact of health insurance status on stage at diagnosis of oropharyngeal cancer","volume":"110","author":"Chen","year":"2007","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO.2017.72.3742","article-title":"Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries","volume":"35","author":"Shih","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: A cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: A SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.2016.68.3805","article-title":"Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma","volume":"35","author":"Go","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"46s","DOI":"10.1200\/JOP.2011.000316","article-title":"Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions","volume":"7","author":"Streeter","year":"2011","journal-title":"J. Oncol. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: A VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1200\/JCO.2016.34.15_suppl.8022","article-title":"Disparities in treatment patterns and outcomes between Caucasian and African American patients with multiple myeloma (MM)","volume":"34","author":"Abouzaid","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial Disparities in Treatment Utilization for Multiple Myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"key":"ref_26","first-page":"1","article-title":"Trends in the multiple myeloma treatment landscape and survival: A U.S. analysis using 2011\u20132019 oncology clinic electronic health record data","volume":"134","author":"Braunlin","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11899-020-00568-3","article-title":"Extramedullary Disease in Multiple Myeloma","volume":"15","author":"Jagosky","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: A population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cncr.31904","article-title":"More evidence on the limited impact of state oral oncology parity laws","volume":"125","author":"Winn","year":"2019","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and Cost of Myeloma Therapy","volume":"38","author":"Rajkumar","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V114.22.1366.1366","article-title":"Multiple Myeloma: Patient out-of-Pocket Costs and Health Care Utilization","volume":"114","author":"Pinsky","year":"2009","journal-title":"Blood"},{"key":"ref_32","unstructured":"(2016). National Cancer Data Base\u2014Data Dictionary PUF, The American College of Surgeons."},{"key":"ref_33","unstructured":"(2019, June 21). United States Department of Agriculture Economic Research Service 2013 Rural-Urban Continuum Codes, Available online: https:\/\/www.ers.usda.gov\/data-products\/rural-urban-continuum-codes\/documentation.aspx."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J. Clin. Epidemiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","article-title":"The role of anatomic and functional staging in myeloma: Description of Durie\/Salmon plus staging system","volume":"42","author":"Durie","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/4\/590\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:19:21Z","timestamp":1760159961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/4\/590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["cancers13040590"],"URL":"https:\/\/doi.org\/10.3390\/cancers13040590","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}